Announcing PSI’s Clinical Trials: A New Chapter in Mental Health Starts July 1, 2025
Psychedelic Science Institute (PSI) officially launched on July 1, 2025, uniting two pioneering mental health organizations to redefine treatment through science, safety, and compassion. Building on the legacy of the Pacific Neuroscience Institute’s TRIP Center (est. 2019 in Santa Monica) and the California Center for Psychedelic Therapy (est. 2018 in Larchmont), PSI brings decades of clinical experience to the emerging field of psychedelic therapy. Our team of internationally recognized clinician-scientists—Drs. Daniel Kelly, Keith Heinzerling, Brooke Balliett, Micah Linton, and Greg Kearns—guides care that is both visionary and grounded in rigorous research and inclusive access.
At PSI, our dual-path model integrates real-world clinical care with FDA-regulated research, delivered across our two TRIP Clinics in Santa Monica and Hollywood. We operate with dedication to patient-centered approaches, equity, and the highest standards of safety and clarity.
Now Open (or Coming Soon): Clinical Trials Accepting Participants
We’re thrilled to announce that several leading-edge clinical trials are now open—or will soon open—for recruitment and patient screening at both our Santa Monica and Hollywood TRIP Clinics:
- Major Depressive Disorder (MDD)
- Usona Institute: Phase 3 trial evaluating psilocybin therapy.
- MindMed: Clinical trial testing LSD-assisted therapy for depression.
- Cybin: Study on CYB003, a novel deuterated psilocybin analog.
- Treatment-Resistant Depression (TRD)
- atai Life Sciences: Investigating RL‑007 and similar compounds for patients who haven’t responded to conventional treatments.
- Generalized Anxiety Disorder (GAD)
- MindMed: Clinical trial exploring MM‑120 (an LSD-derived compound) for anxiety relief.
Why This Matters
Depression, TRD, and anxiety remain some of the most persistent challenges in mental health care, often without reliable solutions through traditional modalities. These studies represent a bold step toward transformative, evidence-based treatments—anchored in rigorous science, medical oversight, and ethical care.
PSI stands as one of the few sites in the United States actively conducting multiple psychedelic-assisted clinical trials, emphasizing scientific integrity, patient autonomy, and inclusive access. We’re proud to serve as an affirming space for LGBTQIA+ and BIPOC communities, striving to ensure these trials reflect and benefit diverse populations.
How to Learn More or Get Involved
We invite patients, caregivers, clinicians, and community advocates to help raise awareness about these critical research opportunities. Here’s how to get started:
- Visit our website at www.psychedelicsci.com to explore current trials and eligibility details.
- Contact our team at either TRIP Clinic to learn more about enrollment, screening, and what participation entails—from consent and preparation through session integration.
- Spread the word: Share information with your networks and refer individuals who may benefit from these studies.
Together, we can accelerate the development of safe, effective therapeutic options and build a future where mental health care is not only innovative but inclusive and accessible.